This trial (NCT01872260) involved a study of triple therapy with BYL719 (PI3K-⍺ inhibitor), LEE011 (CDK4/6 inhibitor), and letrozole in advanced ER+ breast cancer. Here, CDK4 is linked to breast cancer.